ArticleNPJ vaccines2025
Associations between genetic variations of HLA and IGHV, vaccination schedule, and COVID-19 vaccine immunogenicity.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmaceutical design of mRNA vaccines for endemic infectious diseases: integrating antigen discovery with platform engineering.Clinical and experimental vaccine research · 2026Review
- Prospective Biomarkers of SARS-CoV-2 Vaccine Seroconversion in Patients with Haematological Malignancies.Vaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Interindividual genetic variations significantly influenced SARS-CoV-2-specific immunogenicity after vaccination, particularly for human leukocyte antigen (HLA) alleles. However, the mechanisms of different HLA alleles with varying immunogenicity and additional genetic factors related to immunogenicity remained unexplored. This population-based study utilized data of 180,580 vaccinated individuals from the UK Biobank. A genome-wide association study was conducted to identify significant single nucleotide polymorphisms (SNPs) associated with COVID-19 vaccine immunogenicity, identified by immunoglobulin antibody result. We found that SNPs significantly associated with immunogenicity of COVID-19 vaccines were located near the HLA-DQ and IGHV1-69. We further determined HLA-peptide-binding affinities and found that HLA-DQ alleles were significantly associated with immunogenicity due to variations in HLA-peptide binding affinities. Functional genomics data was applied to assess regulatory mechanisms of significant variants near IGHV1-69. Moreover, we employed Mendelian randomization and found that SNPs near IGHV1-69 were associated with immunogenicity by influencing IGHV1-69 expression. Besides, both genetic factors had interactive effects on immunogenicity. These genetic factors modulated the immune response among recipients with different vaccination interval schedules. Furthermore, we observed an interval of five to six weeks that consistently yielded optimal immunogenicity among population, regardless of genetic factors. This study comprehensively demonstrated how interindividual genetic variations affected immunogenicity of COVID-19 vaccines, suggesting the potential for personalized vaccination and administration strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.